Concomitant radiotherapy with chemotherapy in patients with glioblastoma;Chimioradiothérapie concomitante des glioblastomes

Bulletin du Cancer

Volumn 92, Issue 12, 2005, Pages 1065-1072

  Benouaich Amiel, Alexandra ^a   Simon, Jean Marc ^a   Delattre, Jean Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemotherapy; Concomitant radiotherapy; Glioblastoma

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN DERIVATIVE; CYTOTOXIC AGENT; DNA; EPIPODOPHYLLOTOXIN; ETOPOSIDE; NITROSOUREA; TEMOZOLOMIDE; TENIPOSIDE; TETRAZINE DERIVATIVE;

ADULT; AGED; BLOOD TOXICITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; HUMAN; LUNG DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; RADIOSENSITIVITY; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; RADIATION TOLERANCE;

EID: 30544445888     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Int 1999; 91: 1382-90.
2. Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995; 37: 67-73.
3. Figarella-Branger D, Bouvier C. Histological classification of human gliomas: state of art and controversies. Bull Cancer 2005; 92: 301-9.
4. Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery 1980; 7: 435-9.
5. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9.
6. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005; 63: 162-169; (discussion: 169).
7. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239-44.
8. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001; 52: 161-71.
9. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-23.
10. Chinot O. New place of the chemotherapy in gliomas. Bull Canter 2005; 92: 343-54.
11. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos G. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant ghomas in adults. Cancer 1993; 71: 2585-97.
12. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-8.
13. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004; 100: 605-11.
14. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6: 2585-97.
15. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93.
16. Yang X, Darling JL, McMillan TJ, Peacock JH, Steel GG. Radiosensitivity, recovery and dose-rate effect in three human glioma cell lines. Radiother Oncol 1990; 19: 49-56.
17. Milano G, Magne N. Pharmacological consequences of the targeting of epidermal growth factor receptor. Bull Cancer 2003; 90: S197-201.
18. Hoang-Xuan K, Idbaih A, Mokhtari K, Sanson M. Towards a molecular classification of gliomas. Bull Cancer 2005; 92: 310-6.
19. Ochs JS. Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 2004; 58: 941-9.
20. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51: 410-8.
21. Cadirola S, Dutrillaux B. Study of chromosome lesions induced by gamma-rays during the G2 and mitotic phases of the cell cycle. Ann Genet 1984; 27: 154-7.
22. Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol 2000; 27(6 Suppl. 11): 15-20; (discussion: 92-100).
23. Ozkan M, Altinbas M, Er O, Kaplan B, Coskun HS, Karahacioglu E, et al. Postoperative sequential chemoradiotherapy in high-grade cerebral gliomas with fotemustine. J Chemother 2004; 16: 298-302.
24. Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, et al. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Br J Cancer 2003; 88: 496-501.
25. Anders K, Grabenbauer GG, Schuchardt U, Fahlbusch R, Fietkau R, Sauer R, et al. Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma. J Neurooncol 2000; 48: 63-73.
26. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 2003; 5: 79-88.
27. Skov K, MacPhail S. Interaction of platinum drugs with clinically relevant X-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 1991; 20: 221-5.
28. Douple EB, Richmond RC, O'Hara JA, Coughlin CT. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985; 12(suppl. A): 111-24.
29. Dewir L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403-26.
30. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995; 33: 357-64.
31. Mortimer JE, Crowley J, Eyre H, Weiden P, Eltringham J, Stuckey WJ. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer 1992; 69: 1220-3.
32. Stewart DJ, Dahrouge S, Agboola O, Girard A. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 1997; 32: 161-8.
33. Allen J, Siffert J, Donahue B, Nirenberg A, Jakacki R, Robertson P, et al. A phase I/II study of carboplatin combined with hyperfractionatecl radiotherapy for brainstem gliomas. Cancer 1999; 86: 1064-9.
34. Simon JM. Radiotherapy, weekly, carboplatin, and daily etoposide in inoperable biospy proven glioblastoma multiform. Proc Am Soc Clin Oncol 2004; 22: 1544; (abstr.).
35. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673-9.
36. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 1993; 53: 2105-11.
37. Beauchesne P, Soler C, Boniol M, Schmitt T. Response to a phase II study of concomitant-to-sequential use of etoposide and radiation therapy in newly diagnosed malignant gliomas. Am J Clin Oncol 2003; 26: 22-7.
38. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 1998; 82: 355-61.
39. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-66.
40. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in rhe use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2: 552-60.
41. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997; 8: 92-7.
42. Van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000; 47: 779-84.
43. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001; 61: 1957-63.
44. Stupp Z, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-82.
45. Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemure JG, et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer 2004; 101: 2098-105.
46. Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, et al. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 2003; 23: 5159-64.
47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
48. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23: 2372-7.
49. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-4.
50. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
51. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000; 18: 3522-8.
52. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, et al. Phase II trial of carmustine plus O (6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20: 2277-83.
53. De Murcia G, Menissier de Murcia J. Poly (ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994; 19: 172-6.
54. Calabrese CR, Almassy R, Barton S, Batey MA, Calvett AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
55. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicicy by novel poly (adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6: 2860-7.
56. Kiu MC, Chang CN, Cheng WC, Lin TK, Wong CW, Tang SG, et al. Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J Neurooncol 1995; 25: 215-20.
57. Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 1998; 40: 57-63.
58. Brandes AA, Basso U, Vastola F, Tosoni A, Pasetto LM, Jirillo A, et al. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol 2003; 14: 1727-31.
59. Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M. Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys 1998; 40: 661-6.
60. EORTC Brain Tumor Group. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 1991; 27: 568-71.
61. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 1994; 44: 1479-83.
62. Greenberg HS, Chandler WF, Ensminger WD, Sandler H, Junck L, Page MA, et al. Radiosensitization with carotid intra-arterial bromodeoxy-uridine = 5-fluorouradl biomodulation for malignant gliomas. Neurology 1994; 44: 1715-20.
63. Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, et al. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys 1996; 34: 793-802.
64. Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005; 61: 1454-9.